Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.48 |
| ▸ | TEK | Q02763 | 4/20 | 0.48 |
| ▸ | LCK | P06239 | 3/20 | 0.46 |
| ▸ | INSR | P06213 | 2/20 | 0.46 |
| ▸ | LYN | P07948 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | HCK | P08631 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 11/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13897710 | 0.89 | KDR (0.50) | KDRTEKLCKBRAFMAPK14 | |
| SCHEMBL3823481 | 0.88 | KDR (0.64) | KDRTEKLCKINSRLYN | |
| SCHEMBL13898180 | 0.88 | KDR (0.49) | KDRTEKLCKBRAFMAPK14 | |
| SCHEMBL3824106 | 0.83 | KDR (0.60) | KDRTEKLCKINSRLYN | |
| SCHEMBL3823342 | 0.83 | LCK (0.65) | KDRTEKLCKINSRLYN | |
| SCHEMBL13897939 | 0.82 | NR2C2 (0.48) | LYNHCKBRAFMAPK14BTK | |
| SCHEMBL13301979 | 0.79 | LCK (0.54) | KDRLCKINSRLYNSRC | |
| SCHEMBL3830805 | 0.78 | NR2C2 (0.58) | LYNHCKBRAFMAPK14BTK | |
| SCHEMBL3824880 | 0.78 | KDR (0.74) | KDRTEKLCKINSRLYN | |
| SCHEMBL3829573 | 0.78 | KDR (0.68) | KDRTEKLCKSRCBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069327-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069327-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | SRC, BMX, FYN | KDR 95/4885TEK 375/4885LCK 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.